With the demand and supply gap for Remdesivir—a crucial antiviral injection used in the treatment of COVID-19—widening with each passing day, the manufacturers of the drug have reduced their price. The move is likely to benefit thousands of COVID-affected people.
The significant price reduction comes following a request made by the Union government to Remdesivir manufacturers.
The demand for the jab has increased manifold amid the COVID-19 pandemic that is wreaking havoc across India, with the queues outside hospitals and crematoriums getting longer. The reduction in the prices by Remdesivir producing companies is about 39 per cent.
Reduction in Remdesivir price
The sharpest price cut was by Zydus Cadila which reduced the price from Rs 2,800 for a 100 mg vial to Rs 899. Biocon Biologics has reduced the price of the injection from Rs 3,950 to Rs 2,450. Similarly, Dr Reddy’s Laboratories has reduced the price from Rs 5,400 to Rs 2,700.
Cipla has reduced the price from Rs 4,000 to Rs 3,000, Mylan Pharmaceuticals has reduced the price from Rs 4,800 to Rs 3,400, Jubilant Generics has reduced the price from Rs 4,700 to Rs 3,400, and Hetero Healthcare has reduced the price from Rs 5,400 to Rs 3,490.
Meeting held by Centre
The Union government had recently held a meeting with all-existing manufacturers of the drug to discuss measures to increase production and supply and reduce prices of Remdesivir.
Union minister for chemicals and fertilizers Sadananda Gowda tweeted, “On Govt’s intervention, major Manufacturers of #Remdesivir have voluntarily reduced its MRP ranging from Rs 5,400 to less than Rs 3,500 by 15.04.2021…”
To read the latest news in Gujarati click here